ResMed
The 10-second takeaway
For the quarter ended Sep. 30 (Q1), ResMed met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share grew significantly.
Margins grew across the board.
Revenue details
ResMed recorded revenue of $339.7 million. The 11 analysts polled by S&P Capital IQ wanted to see sales of $341.1 million on the same basis. GAAP reported sales were 7.9% higher than the prior-year quarter's $314.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
EPS came in at $0.49. The 10 earnings estimates compiled by S&P Capital IQ predicted $0.46 per share. GAAP EPS of $0.49 for Q1 were 48% higher than the prior-year quarter's $0.33 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Margin details
For the quarter, gross margin was 61.4%, 260 basis points better than the prior-year quarter. Operating margin was 23.7%, 440 basis points better than the prior-year quarter. Net margin was 21.0%, 500 basis points better than the prior-year quarter.
Looking ahead
Next quarter's average estimate for revenue is $364.8 million. On the bottom line, the average EPS estimate is $0.50.
Next year's average estimate for revenue is $1.50 billion. The average EPS estimate is $2.05.
Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 185 members out of 199 rating the stock outperform, and 14 members rating it underperform. Among 55 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 53 give ResMed a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ResMed is outperform, with an average price target of $36.83.
- Add ResMed to My Watchlist.